Changes in Hong Kong stocks | CSPC Group (01093) rose more than 4% in the morning and was approved for clinical trials of nidanib ethanesulfonate inhalation powder

The Zhitong Finance App learned that CSPC Group (01093) rose more than 4% in the morning. As of press release, it had risen 3.89% to HK$8.81, with a turnover of HK$595 million.

According to the news, on January 2, CSPC Pharmaceutical Group announced that the nidanib ethanesulfonate inhalation powder developed by the group has been approved by the China National Drug Administration and can conduct clinical trials in China. This product is the first inhalation preparation approved for clinical use in China to treat pulmonary fibrosis.

Nidanib ethanesulfonate is a multiple tyrosine kinase inhibitor that can slow the process of idiopathic pulmonary fibrosis (IPF). The dosage form currently on the market is an oral softgel. Compared with oral formulations, this product has the advantages of significantly increasing lung exposure, significantly improving lung function, reducing systemic exposure, and significantly reducing gastrointestinal side effects. Preclinical studies have shown that the product can achieve the same efficacy at 1/200 of the oral dose, and has good safety and efficacy.